![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.globenewswire.com/news-release/2024/08/12/2928728/0/en/Erasca-Reports-Second-Quarter-2024-Business-Updates-and-Financial-Results.html
https://www.globenewswire.com//news-release/2024/02/14/2829047/0/en/Erasca-Announces-Two-Clinical-Trial-Collaboration-and-Supply-Agreements-for-Trametinib-to-Evaluate-Naporafenib-Combination-in-SEACRAFT-1-and-SEACRAFT-2-Trials.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-trametinib-dimethyl-sulfoxide-tablets-25094.pdf
https://www.globenewswire.com/news-release/2023/04/25/2653830/0/en/Erasca-Announces-Publication-of-Promising-Clinical-Data-Supporting-the-Therapeutic-Potential-of-Naporafenib-in-Combination-with-Trametinib-in-NRAS-Mutant-Melanoma.html
https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-drug-combo-shows-promise-childhood-brain-cancer-2022-06-06/
https://www.novartis.com/news/media-releases/novartis-reports-late-breaking-data-from-phase-iii-combi-i-trial-spartalizumab-pdr001-tafinlar-and-mekinist-advanced-melanoma
http://www.pharmafile.com/news/559508/novartis-tafinlarmekinist-combo-improves-five-year-relapse-free-survival-new-phase-3-dat
https://www.globenewswire.com/news-release/2020/09/16/2094855/0/en/Novartis-Tafinlar-Mekinist-demonstrates-long-term-relapse-free-survival-benefit-for-high-risk-stage-III-melanoma-patients-in-study-published-in-NEJM.html
https://www.clinicaltrialsarena.com/news/novartis-spartalizumab-data/
http://www.pharmatimes.com/news/novartis_melanoma_combo_fails_in_phiii_1347239
https://endpts.com/hey-wait-up-amgen-and-mirati-boehringer-ingelheim-is-joining-the-kras-crowd-as-early-success-inspires-rivals/
http://www.pmlive.com/pharma_news/half_of_european_cancer_drug_trials_biased,_says_bmj_1302096
https://www.biospace.com/article/array-biopharma-s-triple-drug-combo-could-be-gamechanger-for-colorectal-cancer/
https://www.prnewswire.com/news-releases/long-term-survival-benefit-shown-for-metastatic-melanoma-patients-treated-with-novartis-tafinlar--mekinist-300861778.html
http://www.pmlive.com/pharma_news/novartis_wins_key_adjuvant_tafmek_approval_in_europe_1250603
https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/launches-in-oncology-the-elements-of-success
https://www.tga.gov.au/prescription-medicines-new-or-extended-uses-registered-medicines
https://www.in-pharmatechnologist.com/Article/2018/05/08/FDA-approves-simultaneous-administration-of-Tafinlar-Mekinist-for-ATC
http://www.pharmatimes.com/news/fda_approval_for_novartis_melanoma_combo_1233840
https://www.prnewswire.com/news-releases/novartis-receives-fda-approval-of-tafinlar--mekinist-for-adjuvant-treatment-of-braf-v600-mutant-melanoma-300639403.html
https://www.prnewswire.com/news-releases/novartis-combination-therapy-tafinlar--mekinist-granted-fda-priority-review-for-the-adjuvant-treatment-of-stage-iii-braf-v600-mutation-positive-melanoma-300574944.html
http://www.reuters.com/article/us-novartis-melanoma/novartis-gets-fda-breakthrough-status-for-tafinlar-mekinist-combination-idUSKBN1CS0H1
http://www.fiercepharma.com/marketing/novartis-edges-roche-targeted-melanoma-tafinlar-mekinist-adjuvant-breakthrough
http://www.nasdaq.com/article/novartis-fda-approves-tafinlar-plus-mekinist-for-braf-v600emutant-nsclc-20170623-00004
http://www.nasdaq.com/g00/article/novartis-bristol-myers-collaborate-for-opdivo-combination-cm799724?i10c.referrer=http%3A%2F%2Fc.newsnow.co.uk%2FA%2F888790901%3F-634%3A574%3A0
https://globenewswire.com/news-release/2017/06/05/1008304/0/en/Novartis-announces-clinical-collaboration-with-Bristol-Myers-Squibb-to-evaluate-potential-treatments-in-metastatic-colorectal-cancer.html
http://www.fiercebiotech.com/biotech/novartis-sees-gaps-cancer-pipeline-but-adamant-it-doesn-t-need-io-deal
http://www.fiercebiotech.com/biotech/array-adds-ono-as-japanese-partner-for-mek-braf-combo
http://www.fiercepharma.com/regulatory/novartis-targeted-lung-cancer-combo-picks-up-eu-approval
http://www.nasdaq.com/article/novartis-tafinlar--mekinist-gets-eu-approval-for-braf-v600-positive-nsclc-20170403-00036
http://www.pmlive.com/pharma_news/novartis_gets_lung_cancer_ok_for_tafinlarmekinist_combo_1190650
http://www.pmlive.com/pharma_news/j_and_j_gets_chmp_backing_for_broader_darzalex_use_1187659
http://www.reuters.com/article/us-novartis-chmp-recommendation-idUSKBN1631G5?rpc=401&
http://www.pharmatimes.com/news/smc_clears_three_new_drugs_for_nhs_scotland_use_1129896
http://www.multivu.com/players/English/7694551-novartis-fda-approval-tafinlar-mekinist/
http://www.firstwordpharma.com/node/1319432?tsid=28®ion_id=5#axzz3nCSxAuGG
https://www.bostonglobe.com/lifestyle/health-wellness/2015/08/29/cancer-treatment-precision-medicine-less-precise-than-promised/tqnqPMC7E8nNoDSPWOeUlK/story.html
http://pharmatimes.com/Article/15-07-27/Novartis_melanoma_anaemia_drugs_win_CHMP_favour.aspx
http://www.worldpharmanews.com/novartis/3098-combination-of-novartis-drugs-tafinlarr-and-mekinistr-shows-significant-survival-benefit-in-patients-with-metastatic-melanoma
http://www.fiercepharma.com/story/novartis-unleashes-ma-scouts-gsk-deal-starts-deliver-margins/2015-04-23
http://www.fiercepharma.com/story/novartis-has-fresh-data-support-newly-acquired-cll-drug-arzerra/2015-04-15
http://www.pmlive.com/blogs/the_editors/archive/2023/march/gsk_and_novartis_asset_swap_a_tale_of_two_companies
http://www.fiercepharma.com/story/gsk-deals-done-now-novartis-has-deliver-cancer-growth-pledge/2015-03-02
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/01/news_detail_002247.jsp&mid=WC0b01ac058004d5c1